Web Toolbar by Wibiya
Login | Sign Up AnonymousUser
twiter
New to Comunitee?


or Sign Up with Email

Business

>> AMGEN Latest News

APR 23, 2015 - TheStreet

A Must Read - Share

Santhera -- A Duchenne Drug With Positive Study Results That Few Know About

NEW YORK (TheStreet) -- Santhera Pharmaceuticals (SANN.SW) doesn't get much attention from investors, which is surprising for two reasons. The company is developing a drug to treat Duchenne muscular dystrophy, a rare, inherited muscle-wasting disease very much on Wall Street's radar screen. Santhera has also accomplished something that higher-profile DMD companies BioMarin , PTC Therapeutics and Sarepta Therapeutics have not ...

Tags: Santhera -- A Duchenne Drug With Positive Study Results That Few Know About,  Amgen Latest News

APR 23, 2015 - ABC News

A Must Read - Share

Amgen Tops Estimates With 51 Percent Spike in 1Q Profit

Amgen tops estimates with 51 pct spike in 1Q profit on higher sales, cost cuts; ups forecast

Tags: Amgen Tops Estimates With 51 Percent Spike in 1Q Profit,  Amgen Latest News

APR 22, 2015 - Zacks Investment Research

A Must Read - Share

APR 22, 2015 - TheStreet

A Must Read - Share

Gilead Sciences (GILD) Stock Is the 'Chart of the Day'

NEW YORK (TheStreet) -- Shares of Gilead Sciences  are lower by 0.81% to $104.35 in midday trading on Wednesday. Yesterday, Bernstein analyst Geoff Porges said the pharmaceutical company should acquire Vertex Pharmaceuticals   and its cystic fibrosis drug franchise for $45 billion. The firm said that buying Vertex "makes the most sense, because its future is wholly dependent on CF, where Gilead already has a product ...

Tags: Gilead Sciences (GILD) Stock Is the 'Chart of the Day',  Amgen Latest News

APR 22, 2015 - Zacks Investment Research

A Must Read - Share